Group 1: Core Themes - The 8th China International Import Expo (CIIE) officially opened in Shanghai on November 5, showcasing Bayer Group's commitment to health and hunger elimination with a focus on three major divisions: prescription drugs, consumer health products, and crop science [1] - Bayer exhibited 26 highlight products, including several innovative pharmaceuticals making their debut, such as Eylea® for age-related macular degeneration and a new targeted therapy for lung cancer [1][2] Group 2: Product Highlights - Bayer's pharmaceutical innovations include the global debut of Elinzanetant, a dual neurokinin receptor antagonist for vasomotor symptoms related to menopause, and the acceptance of a new indication for Nubeqa® in metastatic hormone-sensitive prostate cancer [1] - In the consumer health segment, Bayer launched five globally debut products, addressing various health concerns such as allergies and digestive health [2] - The crop science division introduced the new crop health brand "Delaro®" along with two products, and showcased seven new corn varieties from its joint venture, Zhongzhong International [2] Group 3: Local Collaboration and Innovation - Bayer has been deepening local collaborations, including the launch of its third "Yun Yuan Farm" and the "Ling Feng Plan" to empower agricultural retailers [2] - The company is also providing digital pest control services through the "Flying General" platform and building open innovation platforms via Co.Lab and the Yizhuang Open Innovation Center [2]

Core Insights - Bayer is participating in the 8th China International Import Expo (CIIE) with a focus on its mission of "sharing health and eliminating hunger," showcasing its commitment to the Chinese market and its confidence in leveraging local development opportunities [1][2] Group 1: Participation and Commitment - Bayer will have a total exhibition area of 800 square meters across two halls, continuing its presence at the CIIE for the eighth consecutive year, highlighting its long-term commitment to the Chinese market [1] - The company aims to leverage the CIIE as a strategic platform to connect with global innovations and observe China's market opportunities [2] Group 2: Product Innovations - Bayer will showcase approximately 26 highlight exhibits, including 5 global debuts, 8 China debuts, and 13 CIIE debuts, emphasizing its century-long innovation legacy [2] - In the prescription drug sector, Bayer will present innovations in oncology, cardiovascular, ophthalmology, and women's health, including the domestic debut of Eylea® 8mg, which offers significant benefits for patients with age-related macular degeneration [3] - The imaging diagnostics segment will feature locally produced products, including the MEDRAD® Stellant D-CE high-pressure injection system, marking a key milestone in local production [4] - In the consumer health sector, Bayer will introduce new products addressing allergies, digestive health, nutrition, and skin care, including the new member of the Claritin® family, which is recommended for children [5] Group 3: Agricultural Innovations - Bayer will integrate global wisdom with local innovation in agriculture, presenting 7 China debuts and 8 CIIE debuts, including new products in crop health and seed varieties tailored to local farmer needs [6] - The company is committed to sustainable agricultural development in China, showcasing its third regenerative agriculture demonstration farm and various local partnerships aimed at enhancing productivity for smallholder farmers [10] Group 4: Collaborative Efforts - Bayer emphasizes the importance of local collaboration for effective innovation, having established partnerships with startups and academic institutions to drive advancements in healthcare and agricultural technology [7][9] - The company is launching the Bayer Health Consumer Innovation Cooperation Center (CCIP) in 2024 to foster a collaborative ecosystem among top universities and research institutions in China [9] Group 5: Future Outlook - Bayer's participation in the CIIE is seen as a significant opportunity to align with China's development trajectory, aiming to create a better life for the Chinese populace through innovation and collaboration [10]